Mary Grace Baker1, Julie Wang2. 1. Division of Pediatric Allergy & Immunology, Department of Pediatrics, Elliot and Roslyn Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, Box 1198, New York, NY, 10029, USA. 2. Division of Pediatric Allergy & Immunology, Department of Pediatrics, Elliot and Roslyn Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, Box 1198, New York, NY, 10029, USA. julie.wang@mssm.edu.
Abstract
PURPOSE OF REVIEW: Over the last decade, there has been a spark in innovation in the development of therapies for food allergy. Herein, we describe the background and recent advances for food-specific immunotherapies including epicutaneous (EPIT), sublingual (SLIT), and subcutaneous (SCIT). RECENT FINDINGS: Studies have progressed most quickly for the treatment of peanut allergy. Data from the phase 3 EPIT trial add to the accumulating evidence that this will be a viable therapy for peanut allergy. Studies for SLIT and SCIT remain in earlier phases with promising results. This is an exciting era for the treatment of food allergy. Multiple therapies are under investigation, each with their own potential advantages. Specific strengths and limitations of each of these therapies may provide an opportunity to personalize the choice of therapy for individual patients.
PURPOSE OF REVIEW: Over the last decade, there has been a spark in innovation in the development of therapies for food allergy. Herein, we describe the background and recent advances for food-specific immunotherapies including epicutaneous (EPIT), sublingual (SLIT), and subcutaneous (SCIT). RECENT FINDINGS: Studies have progressed most quickly for the treatment of peanutallergy. Data from the phase 3 EPIT trial add to the accumulating evidence that this will be a viable therapy for peanutallergy. Studies for SLIT and SCIT remain in earlier phases with promising results. This is an exciting era for the treatment of food allergy. Multiple therapies are under investigation, each with their own potential advantages. Specific strengths and limitations of each of these therapies may provide an opportunity to personalize the choice of therapy for individual patients.
Authors: Stacie M Jones; Wence K Agbotounou; David M Fleischer; A Wesley Burks; Robert D Pesek; Michael W Harris; Laurent Martin; Claude Thebault; Charles Ruban; Pierre-Henri Benhamou Journal: J Allergy Clin Immunol Date: 2016-02-24 Impact factor: 10.793
Authors: David M Fleischer; Matthew Greenhawt; Gordon Sussman; Philippe Bégin; Anna Nowak-Wegrzyn; Daniel Petroni; Kirsten Beyer; Terri Brown-Whitehorn; Jacques Hebert; Jonathan O'B Hourihane; Dianne E Campbell; Stephanie Leonard; R Sharon Chinthrajah; Jacqueline A Pongracic; Stacie M Jones; Lars Lange; Hey Chong; Todd D Green; Robert Wood; Amarjit Cheema; Susan L Prescott; Peter Smith; William Yang; Edmond S Chan; Aideen Byrne; Amal Assa'ad; J Andrew Bird; Edwin H Kim; Lynda Schneider; Carla M Davis; Bruce J Lanser; Romain Lambert; Wayne Shreffler Journal: JAMA Date: 2019-03-12 Impact factor: 56.272
Authors: Jay A Lieberman; Christopher Weiss; Terence J Furlong; Mati Sicherer; Scott H Sicherer Journal: Ann Allergy Asthma Immunol Date: 2010-10 Impact factor: 6.347
Authors: B M J Flokstra-de Blok; A E J Dubois; B J Vlieg-Boerstra; J N G Oude Elberink; H Raat; A DunnGalvin; J O'B Hourihane; E J Duiverman Journal: Allergy Date: 2009-10-01 Impact factor: 13.146
Authors: L Mondoulet; N Kalach; V Dhelft; T Larcher; C Delayre-Orthez; P H Benhamou; J Spergel; H A Sampson; C Dupont Journal: Clin Exp Allergy Date: 2017-10-20 Impact factor: 5.018
Authors: Elissa M Abrams; Stephanie C Erdle; Scott B Cameron; Lianne Soller; Edmond S Chan Journal: Curr Allergy Asthma Rep Date: 2021-04-30 Impact factor: 4.806